Grant Pickering, serving as the Chief Executive Officer of Vaxcyte Inc., has concluded a series of stock dispositions totaling $1,338,269 on June 26, 2026. The executive's sales were executed in accordance with a Rule 10b5-1 trading plan, which was formally adopted on March 3, 2026. The shares were divested at prices ranging from $54.222 to $56.266 per unit. This financial activity follows a period of significant market appreciation for Vaxcyte, with the stock experiencing a 72% surge over the past year. The equity closed at $56.52 following these transactions, supporting a current market capitalization of $8 billion. This valuation persists despite the biotechnology firm not yet achieving profitability.
Mr. Pickering directly disposed of 22,237 shares of Vaxcyte common stock through three distinct transactions. The first block involved 6,683 shares sold at a weighted-average price of $54.275, with individual sales occurring between $53.755 and $54.75. The second block comprised 9,137 shares sold at a weighted-average price of $55.265, with individual sales occurring between $54.755 and $55.73. The third block consisted of 6,417 shares sold at a weighted-average price of $56.121, with individual sales occurring between $55.815 and $56.60. Following these direct sales, Mr. Pickering retains direct ownership of 452,466 shares of Vaxcyte common stock.
Additional sales were executed through trusts established for the benefit of Mr. Pickering's children. A trust for the benefit of his son sold a total of 900 shares across three transactions. The first transaction involved 312 shares sold at a weighted-average price of $54.345, with individual sales occurring between $53.77 and $54.75. The second transaction involved 356 shares sold at a weighted-average price of $55.226, with individual sales occurring between $54.80 and $55.51. The third transaction involved 332 shares sold at a weighted-average price of $55.993, with individual sales occurring between $55.88 and $56.12. Following these transactions, the trust for the benefit of Mr. Pickering's son holds 134,215 shares.
Furthermore, a trust for the benefit of Mr. Pickering's daughter sold a total of 1,000 shares across three transactions. The first transaction involved 207 shares sold at a weighted-average price of $54.222, with individual sales occurring between $53.77 and $54.42. The second transaction involved 602 shares sold at a weighted-average price of $55.297, with individual sales occurring between $54.80 and $55.72. The third transaction involved 191 shares sold at a weighted-average price of $56.266, with individual sales occurring between $56.00 and $56.54. Following these transactions, the trust for the benefit of Mr. Pickering's daughter holds 134,215 shares.
Analysis from InvestingPro indicates that Vaxcyte is currently trading near its Fair Value, with the stock demonstrating strong price momentum. An InvestingPro Tip notes that the company holds more cash than debt on its balance sheet, providing financial flexibility as it advances its vaccine pipeline. Investors can access 6 additional ProTips and comprehensive analysis through the platform's Pro Research Report, one of 1,400+ available for US equities.
In parallel corporate developments, Vaxcyte announced significant changes to its board of directors. Jacks Lee retired from the board, effective June 17, and subsequently entered a consulting agreement with the company to provide advice on global strategic supply and manufacturing operations. On the same day, Moncef Slaoui was appointed as a Class II director, with his term extending until the annual meeting of stockholders in 2028. The board confirmed that Dr. Slaoui meets the criteria for an independent director under Nasdaq listing standards.
Additionally, Vaxcyte reported the dosing of the first participant in a Phase 1 study for its investigational vaccine candidate, VAX-A1, aimed at preventing Group A Streptococcus infections. This study involves healthy adults aged 18 to 40 years. The company plans to release topline data from the trial in the second half of 2027. These developments reflect Vaxcyte's ongoing efforts in both governance and clinical research.